Author

Carlos González-Muñoza

CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERA OF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROM THE ENEIDA REGISTRY
CLINICAL OUTCOMES IN FAMILIAL VERSUS SPORADIC INFLAMMATORY BOWEL DISEASE DIAGNOSED IN THE ERA OF BIOLOGICAL THERAPIES. PROSPECTIVE DATA FROM THE ENEIDA REGISTRY

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Carlos González-Muñoza  et al.

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Carlos González-Muñoza  et al.

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

Carlos González-Muñoza  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Carlos González-Muñoza  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)
SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)

Carlos González-Muñoza  et al.

LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN’S DISEASE: ECUFIT STUDY FROM GETECCU
LONG-TERM OUTCOMES OF ENTEROCUTANEOUS FISTULA COMPLICATING CROHN’S DISEASE: ECUFIT STUDY FROM GETECCU

Carlos González-Muñoza  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Carlos González-Muñoza  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Carlos González-Muñoza  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

Carlos González-Muñoza  et al.

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU
LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

Carlos González-Muñoza  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY

Carlos González-Muñoza  et al.

Item 1 - 12 / 12
1